

S1 Table. Summary of patient characteristics and responses to imatinib

ID	Characteristics			Prior treatment			Response		
	Age (yr)	Sex	Primary site	Surgery	RTx	Medical treatment	Response	PFS (day)	
1	47	F	ABD	Y (#6)	Y (#2)	Y (#1)	Tamoxifen	PR	187
2	26	F	EXT	Y (#7)	Y (#1)	Y (#1)	Vinblastine/methotrexate	SD	663
3	59	M	EXT	Y(#3)	N	N	-	SD	209
4	66	F	ABD	Y (#2)	Y (#1)	Y (#1)	Tamoxifen	SD	609
5	28	F	EXT	Y (#2)	Y (#1)	N	-	SD	843
6	29	M	EXT	Y (#3)	N	Y (#1)	Methotrexate	SD	826
7	26 ^{a)}	M	ABD	Y (#1)	N	N	-	SD	222
8	31 ^{a)}	M	ABD	Y (#1)	N	N	-	PR	849
9	31	F	EXT	Y (#1)	N	N	-	SD	400
10	57	F	EXT	Y (#3)	Y (#1)	N	-	SD	233
11	34	F	ABD	Y (#1)	N	Y (#1)	Tamoxifen	PD	76
12	42	M	ABD	N	Y (#1)	Y (#2)	Tamoxifen	SD	135
13	58 ^{a)}	M	ABD	Y (#1)	N	N	-	SD	469
14	52	M	ABD	Y (#1)	N	N	-	SD	1,030+
15	19	F	EXT	Y (#2)	N	Y (#1)	Tamoxifen	PD	60
16	19	F	EXT	Y (#3)	N	Y (#1)	Tamoxifen	SD	122
17	40	M	EXT	N	N	Y (#2)	Tamoxifen	SD	629+
18	33	F	EXT	N	N	Y (#2)	Tamoxifen	SD	85
19	25	F	EXT	N	N	Y (#1)	Tamoxifen	PR	749+
20	39	F	ABD	N	N	Y (#1)	Doxorubicin/dacarbazine	PR	982

ABD, abdominal primary site; CTx, chemotherapy; EXT, extra-abdominal primary site; N, no; PD, progressive disease; PFS, progression-free survival; PR, partial response; RTx, radiotherapy; SD, stable disease; Y, yes. + symbol after PFS indicates an ongoing response; # indicates the numbers for each treatment. ^{a)}Familial adenomatous polyposis (n=3).